

# Richard B Rothman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11349537/publications.pdf>

Version: 2024-02-01

361  
papers

17,883  
citations

14653

66  
h-index

21539

114  
g-index

377  
all docs

377  
docs citations

377  
times ranked

8896  
citing authors

#	ARTICLE	IF	CITATIONS
1	The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes. <i>Psychopharmacology</i> , 2019, 236, 915-924.	3.1	12
2	Cocaine-like discriminative stimulus effects of $\alpha$ -norepinephrine-preferring $\alpha$ -monoamine releasers: time course and interaction studies in rhesus monkeys. <i>Psychopharmacology</i> , 2017, 234, 3455-3465.	3.1	8
3	The biogenic amine transporter activity of vinyllogous amphetamine analogs. <i>MedChemComm</i> , 2016, 7, 1657-1663.	3.4	4
4	Interrogating the Activity of Ligands at Monoamine Transporters in Rat Brain Synaptosomes. <i>Neuromethods</i> , 2016, , 41-52.	0.3	2
5	The Case of Posterior Reversible Encephalopathy With Intracranial Hemorrhage was Likely due to Uncontrolled Hypertension, and was Unrelated and Coincidental to Long-term Phentermine Use. <i>Neurologist</i> , 2015, 19, 118-119.	0.7	0
6	Studies of the Biogenic Amine Transporters 15. Identification of Novel Allosteric Dopamine Transporter Ligands with Nanomolar Potency. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 353, 529-538.	2.5	26
7	Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. <i>Drug and Alcohol Dependence</i> , 2015, 147, 1-19.	3.2	116
8	Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 531-539.	5.5	1
9	Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. <i>Psychopharmacology</i> , 2014, 231, 4135-4144.	3.1	64
10	Nonlinear Pharmacokinetics of ( $\pm$ )-3,4-Methylenedioxymethamphetamine (MDMA) and Its Pharmacodynamic Consequences in the Rat. <i>Drug Metabolism and Disposition</i> , 2014, 42, 119-125.	3.3	28
11	Evidence for a Role of Transporter-Mediated Currents in the Depletion of Brain Serotonin Induced by Serotonin Transporter Substrates. <i>Neuropsychopharmacology</i> , 2014, 39, 1355-1365.	5.4	34
12	Alpha-ethyltryptamines as dual dopamine-serotonin releasers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4754-4758.	2.2	28
13	Hybrid Dopamine Uptake Blocker-serotonin Releaser Ligands: A New Twist on Transporter-Focused Therapeutics. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 623-627.	2.8	43
14	Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.. <i>Experimental and Clinical Psychopharmacology</i> , 2014, 22, 274-284.	1.8	16
15	Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphans from diastereoselective alkylation. <i>European Journal of Medicinal Chemistry</i> , 2013, 67, 335-343.	5.5	3
16	Probes for narcotic receptor mediated phenomena. 47.1 Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 3298-3309.	3.0	2
17	Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. <i>European Journal of Pharmacology</i> , 2013, 699, 180-187.	3.5	46
18	Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive "Bath Salts"™ Products. <i>Neuropsychopharmacology</i> , 2013, 38, 552-562.	5.4	361

#	ARTICLE	IF	CITATIONS
19	Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1985-1998.	2.1	15
20	Nonclassical Pharmacology of the Dopamine Transporter: Atypical Inhibitors, Allosteric Modulators, and Partial Substrates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 2-10.	2.5	97
21	Effect of Iboga Alkaloids on $\mu$ -Opioid Receptor-Coupled G Protein Activation. <i>PLoS ONE</i> , 2013, 8, e77262.	2.5	32
22	Studies of the Biogenic Amine Transporters. 14. Identification of Low-Efficacy $\alpha$ -Partial-Substrates for the Biogenic Amine Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 251-262.	2.5	35
23	Probes for narcotic receptor mediated phenomena. 46. N-substituted-2,3,4,9,10,10a-hexahydro-1H-1,4a-(epiminoethano)phenanthren-6- and 8-ols $\alpha$ Carbocyclic relatives of f-oxide-bridged phenylmorphans. <i>European Journal of Medicinal Chemistry</i> , 2012, 58, 557-567.	5.5	6
24	An efficient synthesis of 3-OBn- $\mu$ ,14-epoxy-bridged opiates from naltrexone and identification of a related dual MOR inverse agonist/KOR agonist. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6801-6805.	2.2	3
25	Binding of the Amphetamine-like 1-Phenyl-piperazine to Monoamine Transporters. <i>ACS Chemical Neuroscience</i> , 2012, 3, 693-705.	3.5	28
26	14-Alkoxy- and 14-Acyloxy-pyridomorphinans: $\mu$ Agonist/ $\kappa$ Antagonist Opioid Analgesics with Diminished Tolerance and Dependence Side Effects. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8350-8363.	6.4	54
27	The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue. <i>Neuropsychopharmacology</i> , 2012, 37, 1192-1203.	5.4	386
28	Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective $\mu$ -antagonist activity. <i>European Journal of Medicinal Chemistry</i> , 2012, 50, 44-54.	5.5	9
29	Effects of MDMA and related analogs on plasma 5-HT: Relevance to 5-HT transporters in blood and brain. <i>European Journal of Pharmacology</i> , 2012, 674, 337-344.	3.5	25
30	Semisynthetic neoclerodanes as kappa opioid receptor probes. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 3100-3110.	3.0	31
31	Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A. <i>MedChemComm</i> , 2011, 2, 1217.	3.4	36
32	Neuropharmacology of the Naturally Occurring $\mu$ -Opioid Hallucinogen Salvinorin A. <i>Pharmacological Reviews</i> , 2011, 63, 316-347.	16.0	106
33	In Vivo Effects of Amphetamine Analogs Reveal Evidence for Serotonergic Inhibition of Mesolimbic Dopamine Transmission in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 218-225.	2.5	95
34	Opioid Receptor Probes Derived from Cycloaddition of the Hallucinogen Natural Product Salvinorin A. <i>Journal of Natural Products</i> , 2011, 74, 718-726.	3.0	30
35	Probes for Narcotic Receptor Mediated Phenomena. 41. Unusual Inverse $\mu$ -Agonists and Potent $\mu$ -Opioid Antagonists by Modification of the N-Substituent in Enantiomeric 5-(3-Hydroxyphenyl)morphans. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 957-969.	6.4	16
36	Perinatal lead exposure alters locomotion induced by amphetamine analogs in rats. <i>Life Sciences</i> , 2011, 88, 586-589.	4.3	7

#	ARTICLE	IF	CITATIONS
37	RE: Pulmonary Hypertension Associated with Use of Phentermine?. Yonsei Medical Journal, 2011, 52, 869.	2.2	5
38	Altered Gene Expression in Pulmonary Tissue of Tryptophan Hydroxylase-1 Knockout Mice: Implications for Pulmonary Arterial Hypertension. PLoS ONE, 2011, 6, e17735.	2.5	13
39	Apparent down-regulation of rat brain $\mu$ and $\delta$ -opioid binding sites labelled with [3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramine. Journal of Pharmacy and Pharmacology, 2011, 41, 865-867.	2.4	10
40	Probes for narcotic receptor mediated phenomena. 43. Synthesis of the ortho-a and para-a, and improved synthesis and optical resolution of the ortho-b and para-b oxide-bridged phenylmorphans: Compounds with moderate to low opioid-receptor affinity. Bioorganic and Medicinal Chemistry, 2011, 19, 4330-4337.	3.0	10
41	Probes for narcotic receptor mediated phenomena. Part 42: Synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans. Bioorganic and Medicinal Chemistry, 2011, 19, 3434-3443.	3.0	9
42	Treatment of Obesity With "Combination" Pharmacotherapy. American Journal of Therapeutics, 2010, 17, 596-603.	0.9	25
43	Probes for narcotic receptor mediated phenomena. 40. N-Substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-ols. Bioorganic and Medicinal Chemistry, 2010, 18, 91-99.	3.0	5
44	Identification of a novel "almost neutral" $\mu$ -opioid receptor antagonist in CHO cells expressing the cloned human $\mu$ -opioid receptor. Synapse, 2010, 64, 280-288.	1.2	24
45	Evidence for noncompetitive modulation of substrate-induced serotonin release. Synapse, 2010, 64, 862-869.	1.2	15
46	In Vitro and In Vivo Assessment of Mu Opioid Receptor Constitutive Activity. Methods in Enzymology, 2010, 484, 413-443.	1.0	6
47	Synthesis and Opioid Activity of Enantiomeric <i>N</i> -Substituted 2,3,4,4a,5,6,7,7a-Octahydro-1 <i>H</i> -benzofuro[3,2- <i>c</i> ]isoquinolines. Journal of Medicinal Chemistry, 2010, 53, 1392-1396.	6.4	11
48	Phentermine cardiovascular safety. International Journal of Cardiology, 2010, 144, 241-242.	1.7	0
49	Phentermine cardiovascular safety II: Response to Yosefy Int J Cardiol. 2009 Epub Mar 19. International Journal of Cardiology, 2010, 145, 391-392.	1.7	0
50	Serotonin (5-HT) precursor loading with 5-hydroxy-L-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat. Drug and Alcohol Dependence, 2010, 114, 147-52.	3.2	22
51	Studies of the Biogenic Amine Transporters. 13. Identification of "Agonist" and "Antagonist" Allosteric Modulators of Amphetamine-Induced Dopamine Release. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 718-728.	2.5	25
52	Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 738-746.	2.5	169
53	Serotonergic drugs and valvular heart disease. Expert Opinion on Drug Safety, 2009, 8, 317-329.	2.4	128
54	Effects of Dose and Route of Administration on Pharmacokinetics of ( $\pm$ )-3,4-Methylenedioxymethamphetamine in the Rat. Drug Metabolism and Disposition, 2009, 37, 2163-2170.	3.3	68

#	ARTICLE	IF	CITATIONS
55	Synthetic studies on neoclerodane diterpenes from <i>Salvia splendens</i> : oxidative modifications of ring A. <i>Tetrahedron</i> , 2009, 65, 1708-1715.	1.9	9
56	Design, synthesis, and characterization of $\mu$ -naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2811-2814.	2.2	10
57	Probes for Narcotic Receptor Mediated Phenomena. 39.(1) Enantiomeric N-Substituted Benzofuro[2,3-c]pyridin-6-ols: Synthesis and Topological Relationship to Oxide-Bridged Phenylmorphans(2). <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7570-7579.	6.4	12
58	Changes in feeding and locomotion induced by amphetamine analogs in rats. <i>Drug and Alcohol Dependence</i> , 2009, 100, 234-239.	3.2	30
59	Phentermine cardiovascular safety. <i>American Journal of Emergency Medicine</i> , 2009, 27, 1010-1013.	1.6	18
60	Neural and Cardiac Toxicities Associated With 3,4-Methylenedioxymethamphetamine (MDMA). <i>International Review of Neurobiology</i> , 2009, 88, 257-296.	2.0	41
61	Synthetic studies of neoclerodane diterpenes from <i>Salvia divinorum</i> : role of the furan in affinity for opioid receptors. <i>Organic and Biomolecular Chemistry</i> , 2009, 7, 3748.	2.8	24
62	How Physician Obesity Specialists Use Drugs to Treat Obesity. <i>Obesity</i> , 2009, 17, 1730-1735.	3.0	88
63	Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy. <i>American Journal of Therapeutics</i> , 2009, 16, 354-364.	0.9	60
64	Novel Opioid Antagonists with Mixed/Dual Selectivity. , 2009, , 137-151.		2
65	Synthetic studies of neoclerodane diterpenoids from <i>Salvia splendens</i> and evaluation of opioid receptor affinity. <i>Tetrahedron</i> , 2008, 64, 10041-10048.	1.9	30
66	Probes for Narcotic Receptor Mediated Phenomena. 37. Synthesis and Opioid Binding Affinity of the Final Pair of Oxide-Bridged Phenylmorphans, the Ortho- and Para-b-Isomers and Their <i>N</i> -Phenethyl Analogues, and the Synthesis of the <i>N</i> -Phenethyl Analogues of the Ortho- and Para-d-Isomers. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7866-7881.	6.4	19
67	Serotonin (5-HT) Transporter Ligands Affect Plasma 5-HT in Rats. <i>Annals of the New York Academy of Sciences</i> , 2008, 1139, 268-284.	3.8	20
68	Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. <i>Biochemical Pharmacology</i> , 2008, 75, 2-16.	4.4	77
69	Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 208-217.	2.9	97
70	Salvinorin A Analogs as Probes in Opioid Pharmacology. <i>Chemical Reviews</i> , 2008, 108, 1732-1743.	47.7	90
71	Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction.. <i>Experimental and Clinical Psychopharmacology</i> , 2008, 16, 458-474.	1.8	57
72	Evidence for a $\mu$ -opioid receptor complex in CHO cells co-expressing $\mu$ and $\delta$ opioid peptide receptors. <i>Peptides</i> , 2008, 29, 1424-1431.	2.4	16

#	ARTICLE	IF	CITATIONS
73	Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors. <i>Brain Research Bulletin</i> , 2008, 77, 49-54.	3.0	18
74	Synthesis and pharmacological effects of the enantiomers of the N-phenethyl analogues of the ortho and para e- and f-oxide-bridged phenylmorphans. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 2868.	2.8	14
75	Design and Synthesis of 2- and 3-Substituted-3-phenylpropyl Analogs of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: Role of Amino, Fluoro, Hydroxyl, Methoxyl, Methyl, Methylene, and Oxo Substituents on Affinity for the Dopamine and Serotonin Transporters. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2795-2806.	6.4	11
76	Herkinorin Analogues with Differential $\hat{I}^2$ -Arrestin-2 Interactions. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2421-2431.	6.4	62
77	Studies of the Biogenic Amine Transporters. 12. Identification of Novel Partial Inhibitors of Amphetamine-Induced Dopamine Release. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 286-295.	2.5	24
78	Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 791-797.	2.5	29
79	N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity. <i>Neuropsychopharmacology</i> , 2008, 33, 2303-2312.	5.4	282
80	Dopamine/serotonin releasers as medications for stimulant addictions. <i>Progress in Brain Research</i> , 2008, 172, 385-406.	1.4	38
81	Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions. , 2008, , 311.		3
82	3,4-Methylenedioxyamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. <i>Psychopharmacology</i> , 2007, 189, 407-424.	3.1	214
83	Methamphetamine and Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 132, 1412-1413.	0.8	17
84	Serotonergic responsiveness in human cocaine users. <i>Drug and Alcohol Dependence</i> , 2007, 86, 207-213.	3.2	14
85	Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a $\hat{I}^4$ -agonist $\hat{I}^1$ -antagonist and $\hat{I}^1$ -inverse agonists. <i>Organic and Biomolecular Chemistry</i> , 2007, 5, 1177-1190.	2.8	21
86	Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. <i>AAPS Journal</i> , 2007, 9, E1-E10.	4.4	55
87	Salvinorin A: Allosteric Interactions at the $\hat{I}^4$ -Opioid Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 801-810.	2.5	67
88	Synthetic Studies of Neoclerodane Diterpenes from <i>Salvia divinorum</i> : Preparation and Opioid Receptor Activity of Salvinicin Analogues. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3596-3603.	6.4	46
89	Probes for Narcotic Receptor Mediated Phenomena. 34. Synthesis and Structure-Activity Relationships of a Potent $\hat{I}^4$ -Agonist $\hat{I}^1$ -Antagonist and an Exceedingly Potent Antinociceptive in the Enantiomeric C9-Substituted 5-(3-Hydroxyphenyl)-N-phenylethylmorphans. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3765-3776.	6.4	37
90	DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 1146-1159.	3.0	16

#	ARTICLE	IF	CITATIONS
91	Synthetic studies of neoclerodane diterpenes from <i>Salvia divinorum</i> : Exploration of the 1-position. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6111-6115.	2.2	32
92	A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) $\mu$ -opioid agonists on cellular markers related to opioid tolerance and dependence. <i>Synapse</i> , 2007, 61, 166-175.	1.2	57
93	Antinociceptive and Hypothermic Effects of Salvinorin A Are Abolished in a Novel Strain of $\mu$ -Opioid Receptor-1 Knockout Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 641-648.	2.5	80
94	Design and Synthesis of Promiscuous High-Affinity Monoamine Transporter Ligands: Unraveling Transporter Selectivity. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1766-1772.	6.4	17
95	Synthetic Studies of Neoclerodane Diterpenes from <i>Salvia divinorum</i> : Semisynthesis of Salvinicins A and B and Other Chemical Transformations of Salvinorin A. <i>Journal of Natural Products</i> , 2006, 69, 107-112.	3.0	52
96	Synthesis of Salvinorin A Analogues as Opioid Receptor Probes. <i>Journal of Natural Products</i> , 2006, 69, 914-918.	3.0	52
97	Depressive-Like Effects of the $\mu$ -Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 440-447.	2.5	340
98	Therapeutic Potential of Monoamine Transporter Substrates. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1845-1859.	2.1	53
99	Regulation of the rat brain endothelin system by endogenous $\delta$ -endorphin. <i>Peptides</i> , 2006, 27, 769-774.	2.4	9
100	Dual dopamine/5-HT releasers: potential treatment agents for cocaine addiction. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 612-618.	8.7	39
101	Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 3371-3375.	2.2	14
102	Structure-activity relationships of substituted N-benzyl piperidines in the GBR series: Synthesis of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piperidine, an allosteric modulator of the serotonin transporter. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 3967-3973.	3.0	14
103	Balance between Dopamine and Serotonin Release Modulates Behavioral Effects of Amphetamine-Type Drugs. <i>Annals of the New York Academy of Sciences</i> , 2006, 1074, 245-260.	3.8	108
104	Synthetic studies of neoclerodane diterpenes from <i>Salvia divinorum</i> : Selective modification of the furan ring. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 3170-3174.	2.2	47
105	TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) inhibits the consumption of "snacks" in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 84, 74-83.	2.9	3
106	Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 237-246.	2.5	119
107	Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 604-610.	2.5	56
108	Salvinicins A and B, New Neoclerodane Diterpenes from <i>Salvia divinorum</i> . <i>Organic Letters</i> , 2005, 7, 3017-3020.	4.6	57

#	ARTICLE	IF	CITATIONS
109	N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or "Ecstasy"). <i>Neuropsychopharmacology</i> , 2005, 30, 550-560.	5.4	211
110	Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon <i>Papio anubis</i> . <i>Synapse</i> , 2005, 56, 94-99.	1.2	47
111	Development of a Rationally Designed, Low Abuse Potential, Biogenic Amine Releaser That Suppresses Cocaine Self-Administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1361-1369.	2.5	83
112	(±)-3,4-Methylenedioxymethamphetamine Administration to Rats Does Not Decrease Levels of the Serotonin Transporter Protein or Alter Its Distribution between Endosomes and the Plasma Membrane. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1002-1012.	2.5	56
113	Studies of the Biogenic Amine Transporters. XI. Identification of a 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) Analog That Allosterically Modulates the Serotonin Transporter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 906-915.	2.5	17
114	Chronic Morphine Up-Regulates $G_{i2}$ and Cytoskeletal Proteins in Chinese Hamster Ovary Cells Expressing the Cloned $\mu$ Opioid Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 248-255.	2.5	14
115	Neoclerodane Diterpenes as a Novel Scaffold for $\mu$ Opioid Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4765-4771.	6.4	139
116	Targeted screening for biogenic amine transporters: Potential applications for natural products. <i>Life Sciences</i> , 2005, 78, 512-518.	4.3	4
117	Substituted Amphetamines That Produce Long-Term Serotonin Depletion in Rat Brain ("Neurotoxicity") Do Not Decrease Serotonin Transporter Protein Expression. <i>Annals of the New York Academy of Sciences</i> , 2004, 1025, 151-161.	3.8	12
118	Effects of "Legal" Piperazine Analogs on Dopamine and Serotonin Release in Rat Brain. <i>Annals of the New York Academy of Sciences</i> , 2004, 1025, 189-197.	3.8	66
119	Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned $\mu$ opioid receptor. <i>Synapse</i> , 2004, 52, 209-217.	1.2	21
120	Identification and characterization of a novel allosteric modulator (SoRI-6238) of the serotonin transporter. <i>Synapse</i> , 2004, 53, 176-183.	1.2	24
121	3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. <i>Synapse</i> , 2004, 53, 240-248.	1.2	82
122	A critical structural determinant of opioid receptor interaction with phenolic 5-phenylmorphans. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 4543-4550.	3.0	15
123	Synthesis and Pharmacological Evaluation of 3-(3,4-Dichlorophenyl)-1-indanamine Derivatives as Nonselective Ligands for Biogenic Amine Transporters. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2624-2634.	6.4	56
124	Importance of Phenolic Address Groups in Opioid Kappa Receptor Selective Antagonists. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1070-1073.	6.4	27
125	Identification of Opioid Ligands Possessing Mixed $\mu$ Agonist/ $\kappa$ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydromorphone. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1400-1412.	6.4	58
126	Discovery of the First N-Substituted 4 <sup>2</sup> -Methyl-5-(3-hydroxyphenyl)morphan To Possess Highly Potent and Selective Opioid $\kappa$ Receptor Antagonist Activity. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 281-284.	6.4	18



#	ARTICLE	IF	CITATIONS
127	A study of bile acids as opioid receptor ligands in rat brain membranes. <i>Neuroscience Letters</i> , 2004, 358, 68-70.	2.1	0
128	In Vitro Characterization of Ephedrine-Related Stereoisomers at Biogenic Amine Transporters and the Receptorome Reveals Selective Actions as Norepinephrine Transporter Substrates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 138-145.	2.5	167
129	Monoamine transporters and psychostimulant drugs. <i>European Journal of Pharmacology</i> , 2003, 479, 23-40.	3.5	414
130	Synthesis and Dopamine Transporter Affinity of Chiral 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as Potential Cocaine Abuse Therapeutic Agents. <i>ChemInform</i> , 2003, 34, no.	0.0	0
131	Synthesis, opioid receptor binding, and functional activity of 5 <sup>α</sup> -substituted 17-cyclopropylmethylpyrido[2 <sup>α</sup> :3 <sup>α</sup> :6,7]morphinans. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 529-532.	2.2	18
132	Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 553-556.	2.2	17
133	Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5 <sup>α</sup> -aryl and 5 <sup>α</sup> -heteroaryl 17-cyclopropylmethyl-4,5 <sup>ε</sup> -epoxyprido[2 <sup>α</sup> :3 <sup>α</sup> :6,7]morphinans. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 4143-4154.		6
134	Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor. <i>Synapse</i> , 2003, 47, 1-9.	1.2	10
135	High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. <i>Synapse</i> , 2003, 50, 233-239.	1.2	56
136	Further exploration of 1-[2-[Bis-(4-fluorophenyl)methoxy]ethyl]piperazine (GBR 12909): role of N-aromatic, N-heteroaromatic, and 3-oxygenated N-phenylpropyl substituents on affinity for the dopamine and serotonin transporter. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1385-1389.	2.2	11
137	Diaryldimethylpiperazine ligands with $\mu$ - and $\delta$ -opioid receptor affinity: Synthesis of (+)-4-[(1 $\pm$ R)-1-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 4761-4768.	3.0	5
138	Structure-Activity Relationship Studies of Highly Selective Inhibitors of the Dopamine Transporter: N-Benzylpiperidine Analogues of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1465-1469.	6.4	17
139	3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro. <i>Molecular Pharmacology</i> , 2003, 63, 1223-1229.	2.3	263
140	Identification of (3R)-7-Hydroxy-N-((1S)-1-(((3R,4R)-4-(3-hydroxyphenyl)-1-piperidinyl)ethyl)amino)propan-2-amine (3,4-dimethyl-1-piperidinyl)ethylamine (3,4-DMA) as a Novel Potent and Selective Opioid $\delta$ Receptor Antagonist. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3127-3137.	6.4	74
141	Endogenous CART peptide regulates mu opioid and serotonin 5-HT <sub>2A</sub> receptors. <i>Peptides</i> , 2003, 24, 413-417.	2.4	15
142	(+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 1191-1199.	2.5	70
143	Modulation of Guanosine-5 <sup>α</sup> -[3-thio]triphosphate ([ <sup>35</sup> S]-GTP- $\gamma$ -S) Binding by Opioid Agonists and Antagonists. <i>Reviews in Analgesia</i> , 2003, 7, 83-96.	0.9	1
144	Persistent Antagonism of Methamphetamine-Induced Dopamine Release in Rats Pretreated with GBR12909 Decanoate. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 1190-1197.	2.5	42

#	ARTICLE	IF	CITATIONS
145	Development of Long-Acting Dopamine Transporter Ligands as Potential Cocaine-Abuse Therapeutic Agents: Chiral Hydroxyl-Containing Derivatives of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1321-1329.	6.4	62
146	Discovery of an Opioid $\mu$ Receptor Selective Pure Antagonist from a Library of N-Substituted 4 $\beta$ -Methyl-5-(3-hydroxyphenyl)morphans. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3524-3530.	6.4	26
147	Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 17. Highly $\mu$ Opioid Receptor Selective 14-Alkoxy-Substituted Indolo- and Benzofuromorphinans. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 5378-5383.	6.4	23
148	Piperidine Analogues of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 4371-4374.	6.4	17
149	Anorexogen-Related Cardiac Valvulopathy. <i>Annals of Internal Medicine</i> , 2002, 136, 779.	3.9	4
150	Salvinorin A: A potent naturally occurring nonnitrogenous $\mu$ opioid selective agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11934-11939.	7.1	712
151	Up-regulation of central $\mu$ opioid receptors in a model of hepatic encephalopathy: A potential mechanism for increased sensitivity to morphine in liver failure. <i>Life Sciences</i> , 2002, 70, 1701-1708.	4.3	31
152	Endogenous corticotropin releasing factor regulates adrenergic and opioid receptors. <i>Peptides</i> , 2002, 23, 2177-2180.	2.4	10
153	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. <i>European Journal of Pharmacology</i> , 2002, 447, 51-57.	3.5	67
154	Serotonin releasing agents. <i>Pharmacology Biochemistry and Behavior</i> , 2002, 71, 825-836.	2.9	124
155	Therapeutic and adverse actions of serotonin transporter substrates. , 2002, 95, 73-88.		156
156	Synthesis and biological activity of 8 $\beta$ -substituted hydrocodone indole and hydromorphone indole derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 165-168.	2.2	28
157	Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2225-2228.	2.2	4
158	Probes for Narcotic Receptor Mediated Phenomena. Part 28: New Opioid Antagonists from Enantiomeric Analogues of 5-(3-Hydroxyphenyl)-N-phenylethylmorphans. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 3319-3329.	3.0	31
159	Studies of the biogenic amine transporters. VIII: Identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding. <i>Synapse</i> , 2002, 43, 268-274.	1.2	14
160	Studies of the biogenic amine transporters. 10. Characterization of a novel cocaine binding site in brain membranes prepared from dopamine transporter knockout mice. <i>Synapse</i> , 2002, 44, 94-105.	1.2	6
161	Appetite Suppressants as Agonist Substitution Therapies for Stimulant Dependence. <i>Annals of the New York Academy of Sciences</i> , 2002, 965, 109-126.	3.8	38
162	Preclinical Evaluation of GBR12909 Decanoate as a Long-Acting Medication for Methamphetamine Dependence. <i>Annals of the New York Academy of Sciences</i> , 2002, 965, 92-108.	3.8	16

#	ARTICLE	IF	CITATIONS
163	Synthesis and Biological Evaluation of Tropane-like 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909) Analogues. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3937-3945.	6.4	22
164	Identification of the First trans-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)piperidine Derivative To Possess Highly Potent and Selective Opioid $\mu$ Receptor Antagonist Activity. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 2687-2690.	6.4	110
165	SoRI 9409, a non-peptide opioid $\mu$ receptor agonist/ $\mu$ receptor antagonist, fails to stimulate [35S]-GTP- $\gamma$ -S binding at cloned opioid receptors. <i>Brain Research Bulletin</i> , 2001, 55, 507-511.	3.0	16
166	Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens. <i>Molecular Brain Research</i> , 2001, 87, 184-189.	2.3	18
167	Effect of N-Alkyl and N-Alkenyl Substituents in Noroxymorphindole, 17-Substituted-6,7-dehydro-4,5-epoxy-3,14-dihydroxy-6,7,2,3- $\alpha$ -indolomorphinans, on Opioid Receptor Affinity, Selectivity, and Efficacy. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1471-1474.	6.4	31
168	Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 2883-2885.	2.2	11
169	Opioid peptide receptor studies. 15. Relative efficacy of 4-[(N-allyl-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide and related compounds at the cloned human $\mu$ -opioid receptor. <i>Synapse</i> , 2001, 40, 269-274.	1.2	4
170	Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. <i>Synapse</i> , 2001, 39, 32-41.	1.2	825
171	Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [35S]GTP- $\gamma$ -S functional binding assay. <i>Synapse</i> , 2001, 39, 64-69.	1.2	32
172	Factors Influencing Agonist Potency and Selectivity for the Opioid $\mu$ Receptor Are Revealed in Structure-Activity Relationship Studies of the 4-[(N-Substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 972-987.	6.4	16
173	Chapter 5 Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. <i>The Alkaloids Chemistry and Biology</i> , 2001, 56, 79-113.	2.0	33
174	The Age-Adjusted Mortality Rate From Primary Pulmonary Hypertension, in Age Range 20 to 54 Years, Did Not Increase During the Years of Peak $\alpha$ -Phen/Fen $\alpha$ -Use. <i>Chest</i> , 2000, 118, 1516-1517.	0.8	10
175	Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. , 2000, 35, 222-227.		75
176	Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects. <i>Drug Development Research</i> , 2000, 51, 52-65.	2.9	26
177	4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 1281-1284.	2.2	10
178	Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. <i>Bioorganic and Medicinal Chemistry</i> , 2000, 8, 2689-2692.	3.0	35
179	Methamphetamine Dependence: Medication Development Efforts Based on the Dual Deficit Model of Stimulant Addiction. <i>Annals of the New York Academy of Sciences</i> , 2000, 914, 71-81.	3.8	18
180	Serotonin Transporters, Serotonin Release, and the Mechanism of Fenfluramine Neurotoxicity. <i>Annals of the New York Academy of Sciences</i> , 2000, 914, 172-186.	3.8	18

#	ARTICLE	IF	CITATIONS
181	Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. <i>American Journal of Cardiology</i> , 2000, 85, 913-915.	1.6	38
182	Reply:. <i>American Journal of Cardiology</i> , 2000, 86, 810-811.	1.6	0
183	Evidence for Possible Involvement of 5-HT <sub>2B</sub> Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications. <i>Circulation</i> , 2000, 102, 2836-2841.	1.6	659
184	Comparative neurobiological effects of ibogaine and MK-801 in rats. <i>Drug and Alcohol Dependence</i> , 2000, 59, 143-151.	3.2	11
185	Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog ( $\hat{\alpha}$ ) <sup>+</sup> -HY038. <i>Brain Research Bulletin</i> , 2000, 53, 821-826.	3.0	12
186	Resolution of two [ <sup>35</sup> S]GTP- $\hat{\beta}$ -S binding sites and their response to chronic morphine treatment: A binding surface analysis. <i>Brain Research Bulletin</i> , 2000, 51, 357-362.	3.0	8
187	Synthesis and Transporter Binding Properties of Bridged Piperazine Analogues of 1-{2-[Bis(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine (GBR 12909). <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4840-4849.	6.4	34
188	Probes for Narcotic Receptor-Mediated Phenomena. 27.1 Synthesis and Pharmacological Evaluation of Selective $\hat{\mu}$ -Opioid Receptor Agonists from 4-[( $\hat{\mu}$ R)- $\hat{\mu}$ -(2S,5R)-4-Substituted-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and Their Enantiomers. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3193-3196.	6.4	20
189	Design, Synthesis, and Monoamine Transporter Binding Site Affinities of Methoxy Derivatives of Indatraline. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4868-4876.	6.4	44
190	Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects. <i>Drug Development Research</i> , 2000, 51, 52-65.	2.9	1
191	Aminorex, Fenfluramine, and Chlorphentermine Are Serotonin Transporter Substrates. <i>Circulation</i> , 1999, 100, 869-875.	1.6	201
192	( $\hat{\Delta}$ ) <sup>+</sup> -4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 3053-3056.	2.2	15
193	Optically pure ( $\hat{\Delta}$ ) <sup>+</sup> -4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzamide displays selective binding and full agonist activity for the $\hat{\mu}$ opioid receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 3347-3350.	2.2	14
194	Delta opioid binding selectivity of 3-ether analogs of naltrindole. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 3435-3438.	2.2	13
195	Opioid peptide receptor studies, 11: Involvement of Tyr148, Trp318 and His319 of the rat $\hat{\mu}$ -opioid receptor in binding of $\hat{\mu}$ -selective ligands. , 1999, 32, 23-28.		37
196	Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [ <sup>11</sup> C] WIN35,428 PET scans. , 1999, 32, 44-50.		50
197	Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. <i>Synapse</i> , 1999, 32, 141-145.	1.2	7
198	Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library. , 1999, 33, 239-246.		10

#	ARTICLE	IF	CITATIONS
199	GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [ <sup>11</sup> C]raclopride continuous infusion PET scans. <i>Synapse</i> , 1999, 33, 268-273.	1.2	50
200	Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective $\mu$ antagonist in the [ <sup>35</sup> S]-GTP- $\gamma$ -S functional binding assay. <i>Synapse</i> , 1999, 34, 83-94.	1.2	44
201	Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: Further evidence of kappa receptor heterogeneity. <i>Synapse</i> , 1999, 34, 256-265.	1.2	10
202	Probes for Narcotic Receptor Mediated Phenomena. 26.1-3 Synthesis and Biological Evaluation of Diarylmethylpiperazines and Diarylmethylpiperidines as Novel, Nonpeptidic $\mu$ Opioid Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5455-5463.	6.4	23
203	Chronic exposure to antibodies directed against anti-opiate peptides alter $\mu$ -opioid receptor levels. <i>Peptides</i> , 1999, 20, 1419-1424.	2.4	7
204	Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice. <i>Molecular Brain Research</i> , 1999, 68, 193-197.	2.3	46
205	Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. <i>Molecular Brain Research</i> , 1999, 73, 37-49.	2.3	89
206	Does phentermine inhibit monoamine oxidase?. <i>Lancet, The</i> , 1999, 353, 1362.	13.7	6
207	Synthesis, Opioid Receptor Binding, and Biological Activities of Naltrexone-Derived Pyrido- and Pyrimidomorphinans. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 3527-3538.	6.4	79
208	Oxygenated Analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as Potential Extended-Action Cocaine-Abuse Therapeutic Agents. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5029-5042.	6.4	52
209	$\mu$ Opioid Affinity and Selectivity of 4-Hydroxy-3-methoxyindolomorphinan Analogues Related to Naltrindole. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1673-1679.	6.4	39
210	Opioid Peptide Receptor Studies. 13. Characterization of Opioid Antagonists With the [ <sup>35</sup> S]-GTP- $\gamma$ -S Binding Assay. <i>Analgesia (Elmsford, N Y)</i> , 1999, 4, 27-32.	0.5	10
211	Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction. <i>Annals of the New York Academy of Sciences</i> , 1998, 844, 59-74.	3.8	47
212	In Vivo Correlates of Central Serotonin Function after High-Dose Fenfluramine Administration. <i>Annals of the New York Academy of Sciences</i> , 1998, 844, 138-152.	3.8	7
213	Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat $\mu$ opioid receptor. <i>Synapse</i> , 1998, 28, 117-124.	1.2	12
214	Studies of the biogenic amine transporters. VII. Characterization of a novel cocaine binding site identified with [ <sup>125</sup> I]RTI-55 in membranes prepared from human, monkey and guinea pig caudate. , 1998, 28, 322-338.		25
215	Combined phentermine/fenfluramine administration and central serotonin neurons. <i>Synapse</i> , 1998, 28, 339-342.	1.2	6
216	Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: Concordance with clinical studies. , 1998, 30, 107-111.		25

#	ARTICLE	IF	CITATIONS
217	Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 799-804.	2.2	29
218	N-substituted octahydro-4a-(3-hydroxyphenyl)-10a-methyl-benzo[g]isoquinolines are opioid receptor pure antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 3149-3152.	2.2	9
219	Opioid Peptide Receptor Studies. 8. One of the Mouse Brain $\mu$ NCX Binding Sites is Similar to the Cloned Mouse Opioid $\mu$ Receptor: Further Evidence for Heterogeneity of $\mu$ Opioid Receptors. <i>Peptides</i> , 1998, 19, 343-350.	2.4	7
220	The Effect of FMRFamide Analogs on [35S]GTP- $\gamma$ -S Stimulation in Squid Optic Lobes. <i>Peptides</i> , 1998, 19, 739-747.	2.4	3
221	Opioid peptide receptor studies. 9. Identification of a novel non- $\mu$ - non- $\delta$ -like opioid peptide binding site in rat brain. <i>Peptides</i> , 1998, 19, 1079-1090.	2.4	6
222	Regulation of $\mu$ binding sites after chronic administration of antibodies directed against specific anti-opiate peptides. <i>Peptides</i> , 1998, 19, 1703-1709.	2.4	20
223	Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. <i>Biological Psychiatry</i> , 1998, 44, 578-591.	1.3	87
224	Neurochemical and Neuroendocrine Effects of Ibogaine in Rats: Comparison to MK-801. <i>Annals of the New York Academy of Sciences</i> , 1998, 844, 252-264.	3.8	9
225	Identification of an Opioid $\mu$ Receptor Subtype-Selective N-Substituent for (+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)piperidine. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 5188-5197.	6.4	61
226	N-Substituted 9 $\beta$ -Methyl-5-(3-hydroxyphenyl)morphans Are Opioid Receptor Pure Antagonists. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4143-4149.	6.4	33
227	Synthesis, Opioid Receptor Binding, and Bioassay of Naltrindole Analogues Substituted in the Indolic Benzene Moiety. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 2872-2881.	6.4	39
228	Investigation of the N-Substituent Conformation Governing Potency and $\mu$ Receptor Subtype-Selectivity in (+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)- piperidine Opioid Antagonists. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 1980-1990.	6.4	41
229	Functional Consequences of Central Serotonin Depletion Produced by Repeated Fenfluramine Administration in Rats. <i>Journal of Neuroscience</i> , 1998, 18, 9069-9077.	3.6	44
230	Phentermine/fenfluramine decreases cocaine self-administration in rhesus monkeys. <i>NeuroReport</i> , 1997, 8, 1347-1351.	1.2	51
231	Probes for Narcotic Receptor Mediated Phenomena. 23.1 Synthesis, Opioid Receptor Binding, and Bioassay of the Highly Selective $\mu$ Agonist (+)-4-[(1 $\pm$ R)-1 $\pm$ -((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and Related Novel Nonpeptide $\mu$ Opioid Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 695-704.	6.4	77
232	Heteroaromatic Analogs of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as High-Affinity Dopamine Reuptake Inhibitors. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 705-716.	6.4	63
233	Probes for Narcotic Receptor-Mediated Phenomena. 25.1 Synthesis and Evaluation of N-Alkyl-Substituted (1 $\pm$ -Piperazinylbenzyl)benzamides as Novel, Highly Selective $\mu$ Opioid Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 2936-2947.	6.4	27
234	Effect of dopamine receptor antagonists on cocaine subjective effects: A naturalistic case study. <i>Journal of Substance Abuse Treatment</i> , 1997, 14, 249-258.	2.8	41

#	ARTICLE	IF	CITATIONS
235	Stimulant sensitization in humans. <i>Biological Psychiatry</i> , 1997, 42, 230.	1.3	17
236	$\mu$ 2 Opioid Receptors in Limbic Areas of the Human Brain Are Upregulated by Cocaine in Fatal Overdose Victims. <i>Journal of Neuroscience</i> , 1997, 17, 8225-8233.	3.6	86
237	Libraries of opiate and anti-opiate peptidomimetics containing 2,3-methanoleucine. <i>Bioorganic and Medicinal Chemistry</i> , 1997, 5, 1867-1871.	3.0	11
238	Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats. <i>Psychopharmacology</i> , 1997, 131, 296-306.	3.1	41
239	Opioid Peptide Receptor Studies. 6. The 3-Methylfentanyl Congeners RTI-4614-4 and Its Enantiomers Differ in Efficacy, Potency, and Intrinsic Efficacy as Measured by Stimulation of [ <sup>35</sup> S]GTP- $\gamma$ -S Binding Using Cloned $\mu$ 4-Opioid Receptors. <i>Analgesia (Elmsford, N Y) Tj</i> 0.5 11 11 0.784314	0.5	11
240	Development of Novel, Potent, and Selective Dopamine Reuptake Inhibitors through Alteration of the Piperazine Ring of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). <i>Journal of Medicinal Chemistry</i> , 1996, 39, 4704-4716.	6.4	70
241	Sustained Decrease in Cocaine-Maintained Responding in Rhesus Monkeys with 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl)piperazinyl Decanoate, a Long-Acting Ester Derivative of GBR 12909. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 4689-4691.	6.4	74
242	Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain. <i>Drug and Alcohol Dependence</i> , 1996, 41, 71-74.	3.2	8
243	Downregulation of $\mu$ -opioid binding sites following chronic administration of neuropeptide FF (NPFF) and morphine. <i>Peptides</i> , 1996, 17, 389-397.	2.4	30
244	Pharmacological screen for activities of 12-hydroxyibogaine: a primary metabolite of the indole alkaloid ibogaine. <i>Psychopharmacology</i> , 1996, 127, 10-18.	3.1	73
245	Probes for Narcotic Receptor-Mediated Phenomena. 21. Novel Derivatives of 3-(1,2,3,4,5,11-Hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol-6-yl)-phenols with Improved $\mu$ Opioid Receptor Selectivity. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2081-2086.	6.4	14
246	Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine. <i>NeuroReport</i> , 1996, 8, 7-9.	1.2	15
247	Acute sensitivity vs. context-specific sensitization to cocaine as a function of genotype. <i>Pharmacology Biochemistry and Behavior</i> , 1996, 53, 623-628.	2.9	27
248	Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation. <i>Brain Research</i> , 1996, 737, 215-220.	2.2	25
249	Endocrine responses during acute nicotine withdrawal. <i>Pharmacology Biochemistry and Behavior</i> , 1996, 55, 433-437.	2.9	26
250	Probes for narcotic receptor mediated phenomena 22. (1) synthesis and characterization of optically pure [3H](+)-4-[(1R)-1-((2S, 5R)-4-propyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N, N-diethylbenzamide, [3H]SNC 121, a novel high affinity and select. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1996, 38, 847-850.	1.0	1
251	6 $\alpha$ -[125Iodo]-3, 14-dihydroxy-17-methyl-4, 5 $\epsilon$ -epoxymorphinan ([125I]IOXY-AGO): A potent and selective radioligand for opioid $\mu$ receptors. <i>Synapse</i> , 1995, 19, 105-111.	1.2	1
252	Ligand selectivity of cloned human and rat opioid $\mu$ receptors. <i>Synapse</i> , 1995, 21, 60-64.	1.2	23

#	ARTICLE	IF	CITATIONS
253	Superoxide radicals mediate the biochemical effects of methylenedioxyamphetamine (MDMA): Evidence from using CuZn-superoxide dismutase transgenic mice. <i>Synapse</i> , 1995, 21, 169-176.	1.2	78
254	High-performance liquid chromatographic resolution of synthetic opiate and $\mu$ -opioid peptides from human plasma. <i>Biomedical Applications</i> , 1995, 667, 49-56.	1.7	6
255	A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. <i>Molecular Neurobiology</i> , 1995, 11, 1-19.	4.0	153
256	(E)-8-Benzylidene Derivatives of 2-Methyl-5-(3-hydroxyphenyl)morphans: Highly Selective Ligands for the $\sigma_2$ Receptor Subtype. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 4776-4785.	6.4	11
257	Probes for Narcotic Receptor-Mediated Phenomena. 20. Alteration of Opioid Receptor Subtype Selectivity of the 5-(3-Hydroxyphenyl)morphans by Application of the Message-Address Concept: Preparation of $\delta$ -Opioid Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 1523-1537.	6.4	13
258	Opioid peptide receptor studies. 4. Antisense oligodeoxynucleotide to the delta opioid receptor delineates opioid receptor subtypes. <i>Regulatory Peptides</i> , 1995, 59, 247-253.	1.9	11
259	Opioid peptide receptor studies. 1. Identification of a novel $\kappa$ -opioid receptor binding site in rat brain membranes. <i>Peptides</i> , 1995, 16, 191-198.	2.4	20
260	Opioid peptide receptor studies. 3. Interaction of opioid peptides and other drugs with four subtypes of the $\mu_2$ receptor in guinea pig brain. <i>Peptides</i> , 1995, 16, 1083-1095.	2.4	14
261	Repeated cocaine administration reduces 5-HT <sub>1A</sub> -mediated prolactin secretion in rats. <i>Neuroscience Letters</i> , 1995, 193, 9-12.	2.1	19
262	Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. <i>Life Sciences</i> , 1995, 57, PL45-PL50.	4.3	93
263	Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats. <i>European Journal of Pharmacology</i> , 1995, 282, 87-93.	3.5	46
264	Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. <i>Biological Psychiatry</i> , 1995, 38, 751-755.	1.3	88
265	Enantiomers of Diastereomeric cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropanamides: Synthesis, X-ray Analysis, and Biological Activities. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 1547-1557.	6.4	34
266	Opioid Peptide Receptor Studies 2. [ <sup>3</sup> H]SNC-121, a Novel, Selective, and High-Affinity Ligand for Opioid Delta Receptors. <i>Analgesia (Elmsford, N Y)</i> , 1995, 1, 185-193.	0.5	2
267	RTI-4793-14, a new ligand with high affinity and selectivity for the (+)-MK801-insensitive [3H]1-[1-(2) Tj ETQq1 1 0,784314 rgBT /Ove	1.2	
268	Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-ome-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor binding. <i>Neurochemical Research</i> , 1994, 19, 1159-1163.	3.3	3
269	Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains. <i>Neurochemical Research</i> , 1994, 19, 201-208.	3.3	26
270	An electrophilic affinity ligand based on (+)-MK801 distinguishes PCP site 1 from PCP site 2. <i>Neurochemical Research</i> , 1994, 19, 385-389.	3.3	3



#	ARTICLE	IF	CITATIONS
271	Lack of evidence for context-dependent cocaine-induced sensitization in humans: Preliminary studies. <i>Pharmacology Biochemistry and Behavior</i> , 1994, 49, 583-588.	2.9	75
272	Effects of electroconvulsive shock on the retention of cocaine-induced conditioning. <i>Pharmacology Biochemistry and Behavior</i> , 1994, 49, 399-404.	2.9	3
273	Chronic ICV infusion of morphine and NPFF down-regulate mu opioid receptors in rat brain: A quantitative autoradiographic study. <i>Regulatory Peptides</i> , 1994, 54, 107-108.	1.9	0
274	Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-Famide (NPFF) and A-18-Famide, for opioid $\mu$ , $\delta$ , $\kappa$ , or receptors. <i>Peptides</i> , 1994, 15, 401-404.	2.4	44
275	Letter to the editor. <i>Journal of Substance Abuse Treatment</i> , 1994, 11, 273-275.	2.8	33
276	Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of (+)-4-[( $\alpha$ )- $\alpha$ -(2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl]-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A Highly Selective, Nonpeptide $\delta$ Opioid Receptor Agonist. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 2125-2128.	6.4	210
277	A Marked Change of Receptor Affinity of the 2-Methyl-5-(3-hydroxyphenyl)morphans upon Attachment of an (E)-8-Benzylidene Moiety: Synthesis and Evaluation of a New Class of $\sigma$ Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 3163-3170.	6.4	27
278	Pharmacological characterization of the cloned kappa opioid receptor as a kappa1b subtype. <i>NeuroReport</i> , 1994, 5, 2161-2164.	1.2	28
279	Treatment with antisense oligodeoxynucleotide to the opioid $\delta$ receptor selectively inhibits $\delta$ -agonist antinociception. <i>NeuroReport</i> , 1994, 5, 1049-1052.	1.2	64
280	Evidence for Heterogeneity of Kappa-Opioid Binding Sites: A Review of Data Obtained Using Brain Membranes Depleted of Mu and Delta Binding Sites With Irreversible Agents. <i>Analgesia (Elmsford, N Y)</i> , 1994, 1, 27-49.	0.5	12
281	Identification of a GBR12935 homolog, LR1111, which is over 4,000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters. <i>Synapse</i> , 1993, 14, 34-39.	1.2	72
282	Biosynthesis of dopamine and serotonin in the rat brain after repeated cocaine injections: A microdissection mapping study. <i>Synapse</i> , 1993, 14, 40-50.	1.2	54
283	Effects of acute and chronic cocaine on the activity of tuberoinfundibular dopamine neurons in the rat. <i>Brain Research</i> , 1993, 608, 175-179.	2.2	21
284	Studies of the biogenic amine transporters. II. A brief study on the use of [ $^3$ H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. <i>Life Sciences</i> , 1993, 53, PL267-PL272.	4.3	51
285	Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the (enkephalin-sensitive) binding site. <i>Peptides</i> , 1993, 14, 17-20.	2.4	26
286	Differential binding of opioid peptides and other drugs to two subtypes of opioid binding sites in mouse brain: Further evidence for $\delta$ receptor heterogeneity. <i>Peptides</i> , 1993, 14, 893-907.	2.4	36
287	Chronic intracerebroventricular infusion of the antiopioid peptide, Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH <sub>2</sub> (NPFF), downregulates mu opioid binding sites in rat brain. <i>Peptides</i> , 1993, 14, 1271-1277.	2.4	38
288	Selective labeling of $\delta$ opioid receptors in rat brain by [ $^{125}$ I]IOXY: Interaction of opioid peptides and other drugs with multiple $\delta$ binding sites. <i>Peptides</i> , 1993, 14, 1279-1293.	2.4	30

#	ARTICLE	IF	CITATIONS
289	Withdrawal from chronic cocaine enhances behavioral sensitivity to the 5-HT <sub>2</sub> /1C agonist DOI. <i>Biological Psychiatry</i> , 1993, 34, 576-577.	1.3	18
290	Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. <i>Gastroenterology</i> , 1992, 103, 630-635.	1.3	167
291	Central mu-opioid receptors are down-regulated in a rat model of cholestasis. <i>Journal of Hepatology</i> , 1992, 15, 220-224.	3.7	139
292	Probes for narcotic receptor mediated phenomena. 18. Epimeric 6.alpha.- and 6.beta.-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5.alpha.-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [ <sup>125</sup> I]-6.beta.-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5.alpha.-epoxymorphinan. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 2826-2835.	6.4	28
293	Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that $\delta$ ligands are noncompetitive inhibitors of the $\mu$ cx opioid peptide binding site. <i>Peptides</i> , 1992, 13, 1137-1143.	2.4	15
294	Interaction of opioid peptides and other drugs with multiple $\mu$ cx binding sites in rat brain: Further evidence for heterogeneity. <i>Peptides</i> , 1992, 13, 1207-1213.	2.4	18
295	Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences. <i>Peptides</i> , 1992, 13, 977-987.	2.4	47
296	A study of the effect of the irreversible delta receptor antagonist [d-Ala <sup>2</sup> ,Leu <sup>5</sup> ,Cys <sup>6</sup> ]Enkephalin on and opioid binding sites in vitro and in vivo. <i>Peptides</i> , 1992, 13, 691-694.	2.4	15
297	A review of the role of anti-opioid peptides in morphine tolerance and dependence. <i>Synapse</i> , 1992, 12, 129-138.	1.2	156
298	MPTP lesions of the nigrostriatal dopaminergic projection decrease [ <sup>3</sup> H]1-[1-(2-thienyl)cyclohexyl]-piperidine binding to PCP site 2: Further evidence that PCP site 2 is associated with the biogenic amine reuptake complex. <i>Neurochemical Research</i> , 1992, 17, 261-264.	3.3	8
299	[ <sup>3</sup> H]cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: Allosteric modulation by paroxetine. <i>Neurochemical Research</i> , 1992, 17, 1275-1283.	3.3	24
300	Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. <i>Pharmacology Biochemistry and Behavior</i> , 1992, 43, 1135-1142.	2.9	77
301	RTI-46144: An analog of (+)-cis-3-methylfentanyl with a 27,000-fold binding selectivity for mu versus delta opioid binding sites. <i>Life Sciences</i> , 1991, 48, PL111-PL116.	4.3	35
302	Preliminary ligand binding data for subtypes of the delta opioid receptor in rat brain membranes. <i>Life Sciences</i> , 1991, 49, PL141-PL146.	4.3	28
303	Probing the opioid receptor complex with (+)-trans-superfit. I. Evidence that [D-Pen <sup>2</sup> ,D-Pen <sup>5</sup> ]enkephalin interacts with high affinity at the $\mu$ cx binding site. <i>Peptides</i> , 1991, 12, 359-364.	2.4	21
304	Upregulation of the opioid receptor complex by the chronic administration of morphine: A biochemical marker related to the development of tolerance and dependence. <i>Peptides</i> , 1991, 12, 151-160.	2.4	55
305	GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. <i>Pharmacology Biochemistry and Behavior</i> , 1991, 40, 387-397.	2.9	113
306	Interaction of $\beta$ -funtrexamine with [ <sup>3</sup> H]cycloFOXY binding in rat brain: Further evidence that $\beta$ -FNA alkylates the opioid receptor complex. <i>Synapse</i> , 1991, 8, 86-99.	1.2	22

#	ARTICLE	IF	CITATIONS
307	[3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: Further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. <i>Synapse</i> , 1991, 8, 289-300.	1.2	29
308	Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligands. <i>Journal of Medicinal Chemistry</i> , 1990, 33, 1171-1176.	6.4	18
309	Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. <i>Peptides</i> , 1990, 11, 311-331.	2.4	141
310	The potent opioid agonist, (+)-cis-3-methylfentanyl binds pseudoirreversibly to the opioid receptor complex in vitro and in vivo: Evidence for a novel mechanism of action. <i>Life Sciences</i> , 1990, 47, 2231-2240.	4.3	7
311	High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug development. <i>Life Sciences</i> , 1990, 46, PL17-PL21.	4.3	118
312	Pseudoallosteric modulation by (+)-MK801 of NMDA-coupled phencyclidine binding sites. <i>Life Sciences</i> , 1990, 47, PL77-PL82.	4.3	3
313	Selective and enantiospecific acylation of .kappa.-opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide. Demonstration of .kappa. receptor heterogeneity. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 281-283.	6.4	42
314	Probes for narcotic receptor mediated phenomena. 15. (3S,4S)-(+)-trans-3-Methylfentanyl isothiocyanate, a potent site-directed acylating agent for the .delta.-opioid receptors in vitro. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 1392-1398.	6.4	32
315	Pharmacological activities of optically pure enantiomers of the $\mu$ opioid agonist, U50,488, and its cis diastereomer: evidence for three $\mu$ receptor subtypes. <i>European Journal of Pharmacology</i> , 1989, 167, 345-353.	3.5	48
316	Chronic administration of morphine and naltrexone up-regulate $\mu$ -opioid binding sites labeled by [3H][D-Ala <sup>2</sup> , MePhe <sup>4</sup> , Gly-ol <sup>5</sup> ]enkephalin: further evidence for two $\mu$ -binding sites. <i>European Journal of Pharmacology</i> , 1989, 160, 71-82.	3.5	82
317	Modulation of $\mu$ -mediated antinociception by $\mu$ agonists: characterization with antagonists. <i>European Journal of Pharmacology</i> , 1989, 169, 43-52.	3.5	84
318	Synthesis of an affinity ligand (â€ˆUPHITâ€™) for in vivo acylation of the $\mu$ -opioid receptor. <i>FEBS Letters</i> , 1989, 249, 178-182.	2.8	19
319	Tight binding dopamine reuptake inhibitors as cocaine antagonists. <i>FEBS Letters</i> , 1989, 257, 341-344.	2.8	53
320	Chronic morphine increases $\mu$ -opiate receptor binding in rat brain: a quantitative autoradiographic study. <i>Brain Research</i> , 1989, 477, 382-386.	2.2	94
321	Alterations in the stereochemistry of the .kappa.-selective opioid agonist U50,488 result in high-affinity .sigma. ligands. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 1996-2002.	6.4	71
322	Physiological regulation of neurohypophyseal $\mu$ -opiate receptors. <i>Brain Research</i> , 1988, 443, 398-402.	2.2	19
323	Tritiated-6-beta-fluoro-6-desoxy-oxymorphone â€ˆ[3H] FOXYâ€™: a new ligand and photoaffinity probe for the $\mu$ opioid receptors. <i>Neuropeptides</i> , 1988, 11, 1-6.	2.2	12
324	LY164929: a highly selective ligand for the lower affinity [3H]D-Ala <sup>2</sup> -D-Leu <sup>5</sup> -enkephalin binding site. <i>Neuropeptides</i> , 1988, 11, 13-16.	2.2	29

#	ARTICLE	IF	CITATIONS
325	An examination of the opiate receptor subtypes labeled by [3H]cyclofoxy: An opiate antagonist suitable for positron emission tomography. <i>Biological Psychiatry</i> , 1988, 23, 435-458.	1.3	29
326	Interaction of enantiomeric pairs of opiates with phencyclidine binding sites in rat brain: Identification of (+) pentazocine as a ligand potentially suitable for imaging sigma binding sites using positron emission tomography. <i>Neuropeptides</i> , 1988, 12, 1-5.	2.2	22
327	Increased cortical serotonin-2 (5-HT-2) receptors in the iminodipropionitrile (IDPN)-model of persistent dyskinesia in the rat. <i>Neuropeptides</i> , 1987, 10, 175-180.	2.2	12
328	Rat brain PCP receptors: Alterations in binding parameters following chronic administration of opiate agonists and antagonists. <i>Neuropeptides</i> , 1987, 10, 201-205.	2.2	1
329	Intracerebroventricular administration of superFIT and its enantiomer to rats: Evidence for in vivo acylation of [3H]DADL binding sites. <i>Neuropeptides</i> , 1987, 9, 207-210.	2.2	1
330	[3H]cyclofoxy, a ligand suitable for positron emission tomography, labels mu and kappa opioid receptors. <i>Neuropeptides</i> , 1987, 10, 235-239.	2.2	11
331	Chronic morphine upregulates a $\delta$ -opiate binding site labeled by [3H]cycloFOXY: a novel opiate antagonist suitable for positron emission tomography. <i>European Journal of Pharmacology</i> , 1987, 142, 73-81.	3.5	31
332	Synthesis and absolute configuration of optically pure enantiomers of a $\delta$ -opioid receptor selective agonist. <i>FEBS Letters</i> , 1987, 223, 335-339.	2.8	27
333	Autoradiographic evidence for two classes of mu opioid binding sites in rat brain using [125I]FK33824. <i>Peptides</i> , 1987, 8, 1015-1021.	2.4	59
334	Unexpectedly high levels of opioid peptides in rat brain membranes. <i>Peptides</i> , 1987, 8, 645-649.	2.4	10
335	Distribution of opiate receptor subtypes and enkephalin and dynorphin immunoreactivity in the hippocampus of squirrel, guinea pig, rat, and hamster. <i>Journal of Comparative Neurology</i> , 1987, 255, 497-510.	1.6	169
336	A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain. <i>Brain Research</i> , 1986, 385, 273-281.	2.2	96
337	Morphine tolerance increases $\delta$ -noncompetitive $\delta$ binding sites. <i>European Journal of Pharmacology</i> , 1986, 124, 113-119.	3.5	84
338	Decreased striatal opiate $\delta$ -receptors in the rat model of persistent dyskinesia induced by iminodipropionitrile. <i>Neuroscience Letters</i> , 1986, 72, 84-86.	2.1	22
339	Chronic iminodipropionitrile (IDPN) causes no changes in the rat brain phencyclidine (PCP) receptor. <i>Neuropeptides</i> , 1986, 7, 259-263.	2.2	4
340	Autoradiographic localization of $\delta$ - and $\delta$ -opiate receptors in the forebrain of the rat. <i>Brain Research</i> , 1986, 378, 49-60.	2.2	172
341	Opiate receptors in rat pituitary are confined to the neural lobe and are exclusively kappa. <i>Brain Research</i> , 1986, 382, 365-371.	2.2	132
342	Leucine enkephalin noncompetitively inhibits the binding of [3H]naloxone to the opiate mu-recognition site: Evidence for $\delta$ - $\mu$ binding site interactions in vitro. <i>Neuropeptides</i> , 1985, 6, 351-363.	2.2	33

#	ARTICLE	IF	CITATIONS
343	Evidence that the delta-selective alkylating agent, FIT, alters the mu-noncompetitive opiate delta binding site. <i>Neuropeptides</i> , 1985, 6, 227-237.	2.2	10
344	Preparation of rat brain membranes highly enriched with opiate kappa binding sites using site-directed acylating agents: Optimization of assay conditions. <i>Neuropeptides</i> , 1985, 6, 503-516.	2.2	34
345	Effect of $\beta$ -FNA on Opiate $\mu$ Receptor Binding. <i>Journal of Neurochemistry</i> , 1984, 43, 1197-1199.	3.9	16
346	Tritiated-6-beta-fluoro-6-desoxy-oxymorphone: A highly selective ligand for the opiate mu receptor whose binding is characterized by low nonspecific binding. <i>Neuropeptides</i> , 1984, 4, 311-317.	2.2	12
347	Autoradiographic localization of a novel peptide binding site in rat brain using the substance P analog, eleldoisin. <i>Neuropeptides</i> , 1984, 4, 343-349.	2.2	38
348	Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: Evidence for a two-site allosteric model. <i>Neuropeptides</i> , 1984, 4, 201-215.	2.2	57
349	Morphine noncompetitively inhibits [3H]leucine enkephalin binding to membranes lacking type-II delta binding sites: Evidence for a two-site allosteric model. <i>Neuropeptides</i> , 1984, 4, 257-260.	2.2	11
350	Ionic conditions differentially affect 3H-DADL binding to type-I and type-II opiate delta receptors in vitro. <i>Neuropeptides</i> , 1984, 4, 261-268.	2.2	4
351	Visualization of rat brain receptors for the neuropeptide, substance P. <i>Brain Research</i> , 1984, 309, 47-54.	2.2	104
352	Multiple opioid receptors: An examination of the dissociation of [3H]leucine enkephalin from rat brain membranes. <i>Neurochemical Research</i> , 1983, 8, 179-184.	3.3	1
353	Interaction of leucine enkephalin with (3H)naloxone binding in rat brain: Evidence for an opioid receptor complex. <i>Neurochemical Research</i> , 1983, 8, 913-931.	3.3	23
354	Analysis of binding surfaces: A methodology appropriate for the investigation of complex receptor mechanisms and multiple neurotransmitter receptors. <i>Neuropeptides</i> , 1983, 4, 41-44.	2.2	18
355	Multidimensional analysis of ligand binding data: Application to opioid receptors. <i>Neuropeptides</i> , 1983, 3, 367-377.	2.2	16
356	Binding of radiolabeled opiates to slide-mounted sections of molded minced rat brain: A novel method for conducting radioreceptor assays. <i>Neuropeptides</i> , 1983, 3, 493-499.	2.2	32
357	Effect of $\beta$ -FNA on opiate receptor binding: Preliminary evidence for two types of $\mu$ receptors. <i>European Journal of Pharmacology</i> , 1983, 95, 147-148.	3.5	30
358	Mu and delta receptors: Their role in analgesia and in the differential effects of opioid peptides on analgesia. <i>Life Sciences</i> , 1982, 30, 1443-1455.	4.3	223
359	Interaction of naloxone with the opioid receptor complex in vitro. <i>Neurochemical Research</i> , 1982, 7, 1375-1384.	3.3	10
360	Allosteric modulation by leucine-enkephalin of [3H]naloxone binding in rat brain. <i>European Journal of Pharmacology</i> , 1981, 72, 365-368.	3.5	55

#	ARTICLE	IF	CITATIONS
361	ALTERATIONS IN THE BINDING OF [3H]LEUCINE-ENKEPHALIN TO STRIATAL MEMBRANES BY ENDOGENOUS FACTORS. <i>Journal of Neurochemistry</i> , 1979, 33, 191-200.	3.9	5